4-Thiazolecarboxylic Acid

β-Lactam Antibiotic Side-Chain Modification: Aztreonam Synthetic Precursor

In the commercial-scale synthesis of the monobactam antibiotic aztreonam, 4-thiazolecarboxylic acid functions as the critical aminothiazole side-chain progenitor. The compound is activated via the mixed anhydride method using ethyl chloroformate in anhydrous dichloromethane at -15°C to -5°C, subsequently coupled to the β-lactam nucleus with a molar feed ratio of 1.05:1 relative to the azetidinone intermediate. Process engineers have documented a narrow thermal window during activation: deviation below -18°C causes crystallization of the triethylamine hydrochloride salt in the transfer line, while excursion above -8°C triggers premature decarboxylation of the mixed anhydride, generating a thiazole impurity that co-elutes with the target compound during preparative HPLC purification. The coupling step proceeds in a jacketed 5000-L glass-lined reactor with anchor agitator at 85–120 rpm, achieving 92–94% conversion within 4.5 hours as tracked by in-process TLC. Post-reaction workup involves sequential washes with 5% w/v sodium bicarbonate and 1N HCl, followed by vacuum distillation of the solvent at ≤40°C jacket temperature to prevent thermal degradation. The crude product is recrystallized from isopropanol/water (70:30 v/v) to yield aztreonam with polymorphic Form A, confirmed by XRPD.

• Industry compliance standards: USP ⟨797⟩ Pharmaceutical Compounding – Sterile Preparations; ICH Q3C(R8) residual solvent limits (dichloromethane Class 2, limit 600 ppm); 21 CFR 211.84 testing and approval of incoming components; EP 2.2.46 Chromatographic Separation Techniques for related substances.
• Formulation addition ratio: 1.0–1.2 molar equivalents relative to the azetidinone core; excess 0.05 equivalents scavenged during aqueous bicarbonate wash.
• Downstream manufacturing process: Mixed anhydride activation → cryogenic coupling → liquid-liquid extraction → solvent swap distillation → crystallization → vacuum tray drying (50°C, ≤10 mbar, 16 hours) → micronization via air-jet mill to D90 ≤10 µm for injectable formulation.
• Finished product type: Aztreonam for injection USP (lyophilized powder in 1 g and 2 g vials); aztreonam lysine salt for nebulizer solution (Cayston® inhalation formulation).

Can the Heteroaryl Carboxylate Moiety Modulate Dirhodium(II) Catalyst Enantioselectivity in Cyclopropanation?

4-Thiazolecarboxylic acid is employed as a bridging ligand in the synthesis of chiral dirhodium(II) tetracarboxylate catalysts used for asymmetric intramolecular cyclopropanation. The thiazole ring nitrogen introduces an electron-withdrawing character that shifts the Rh-Rh HOMO-LUMO gap by approximately 0.3 eV relative to the acetate analogue, as measured by cyclic voltammetry on a glassy carbon electrode in 0.1 M TBAPF₆/acetonitrile. This electronic modulation translates to measurable improvements in enantioselectivity for certain styrenyl diazoacetate substrates. On a pilot scale, catalyst preparation involves refluxing rhodium(II) acetate dimer with 4–6 equivalents of 4-thiazolecarboxylic acid in chlorobenzene under a Soxhlet extractor packed with 4Å molecular sieves. The ligand exchange equilibrium is driven by azeotropic removal of acetic acid; incomplete removal results in mixed-ligand species that generate variable enantiomeric excess (ee) batch-to-batch. A production campaign at a US-based CRO recorded ee values ranging from 87% to 93% across five catalyst lots, with the variance traced to residual moisture in the molecular sieves via Karl Fischer titration. The purified catalyst is isolated by precipitation from hexane and stored under argon with ≤5 ppm O₂ headspace to prevent μ-oxo dimer formation, a known deactivation pathway that manifests as a green-to-brown color shift. Catalyst loading in cyclopropanation trials runs at 0.5–1.0 mol% with diazo compound addition via syringe pump over 4–8 hours to maintain substrate:catalyst ratio control.

• Industry compliance standards: ASTM E537-12 thermal stability by DSC (screening for diazo compound exotherms); ICH Q11 Development and Manufacture of Drug Substances (starting material designation); EU GMP Annex 15 qualification of purification columns; OSHA 1910.1200 Hazard Communication for diazomethane handling.
• Formulation addition ratio: Ligand exchange stoichiometry 4–6 eq relative to Rh₂(OAc)₄; catalytic loading 0.5–1.0 mol% in substrate.
• Downstream manufacturing process: Soxhlet-mediated ligand exchange → hot filtration through Celite pad → vacuum concentration to 20% original volume → precipitation in hexane → Schlenk-line filtration under argon → vacuum drying (60°C, 24 hours) → glovebox packaging (≤1 ppm H₂O, ≤1 ppm O₂).
• Finished product type: Dirhodium(II) tetrakis(4-thiazolecarboxylate) catalyst as green crystalline solid; applied in synthesis of cyclopropyl amino acid building blocks for hepatitis C protease inhibitors.

The choice of 4-thiazolecarboxylic acid over its 5-thiazolecarboxylic acid isomer in succinate dehydrogenase inhibitor (SDHI) fungicide synthesis is dictated by the carboxy group position required for amide coupling to the pyrazole-4-carboxamide pharmacophore. Commercial manufacturing of isopyrazam and sedaxane involves activation of the thiazole acid to the corresponding acid chloride using thionyl chloride in toluene at reflux with catalytic DMF (0.5 mol%). A documented process bottleneck at production scale is the formation of a dark, tarry byproduct when the batch temperature exceeds 85°C during SOCl₂ distillation. This tar fouls the reboiler of the wiped-film evaporator used for solvent recovery, necessitating a caustic cleaning cycle every 8–12 batches and contributing 4–6% yield loss per campaign. The acid chloride intermediate is telescoped without isolation into the amidation step, where it reacts with the substituted pyrazole amine in dichloromethane at 0–5°C with 1.1 equivalents of triethylamine. Process analytical technology (PAT) via ReactIR monitors the disappearance of the acid chloride carbonyl stretch at 1790 cm⁻¹; the endpoint is declared when peak area drops below 2% of initial. The crude SDHI active is crystallized from methanol/water, filtered through a Nutsche filter-dryer, and dried under vacuum at 60°C to achieve ≤0.5% water content by weight. Particle size is controlled to D50 2–5 µm via wet-milling in a horizontal bead mill charged with 0.6–0.8 mm yttria-stabilized zirconia beads, targeting the suspension concentrate formulation specification.

• Industry compliance standards: FAO JMPS guidelines for technical material equivalence; CIPAC MT 46.3 accelerated storage stability (54°C, 14 days); EC Regulation 1107/2009 active substance approval dossier; OECD Test No. 111 hydrolysis as a function of pH for environmental fate; 40 CFR Part 180 tolerance exemptions for residues in food commodities.
• Formulation addition ratio: 1.0–1.15 molar equivalents relative to pyrazole amine; final active ingredient constitutes 200–250 g/L in suspension concentrate formulation.
• Downstream manufacturing process: Acid chloride generation → telescoped amidation → aqueous workup with 10% NaCl brine → solvent exchange to methanol → cooling crystallization (−10°C, 3-hour hold) → agitated Nutsche filtration → vacuum drying (65°C, 48 hours) → jet milling for pre-grind → wet bead milling → spray drying onto silica carrier for water-dispersible granule variants.
• Finished product type: Isopyrazam 125 g/L SC and sedaxane-based seed treatment flowable concentrates; water-dispersible granules containing 50% w/w active for foliar application in cereal crops.

Published data for this specific configuration is limited. Incorporation of 4-thiazolecarboxylic acid into the backbone of lanthanide-based metal-organic frameworks (Ln-MOFs) has been investigated at the gram scale in academic laboratories rather than industrial production lines. The ligand is dissolved in DMF with europium(III) nitrate hexahydrate and 4,4'-bipyridyl as co-ligand, solvothermally treated in a Teflon-lined Parr autoclave at 120°C for 48 hours. The resulting crystalline material exhibits characteristic ⁵D₀→⁷F₂ electric dipole transition at 616 nm upon excitation at 315 nm, with luminescence quantum yield reported at 18–23% in solid-state measurements using an integrating sphere. Sensing experiments toward nitroaromatic compounds have demonstrated Stern-Volmer quenching constants on the order of 10³ M⁻¹ for 2,4-dinitrotoluene in acetonitrile suspension. Scale-up challenges remain unaddressed: the solvothermal batch process is inherently limited by heat transfer in vessels exceeding 2-L internal volume, and the framework collapses irreversibly upon activation if the solvent exchange from DMF to methanol proceeds faster than the critical rate of 0.5 mL/min per gram of MOF. No standardized ASTM or ISO method exists for MOF-based sensor qualification, and the material has not progressed beyond laboratory proof-of-concept demonstrations.

• Industry compliance standards: No established regulatory framework for MOF-based sensors; applicable general standards include IEC 61010-1 safety requirements for electrical measurement equipment and ISO 10110-7 surface imperfection tolerances for optical components into which the MOF might be integrated.
• Formulation addition ratio: Ligand-to-metal molar ratio 2:1 (4-thiazolecarboxylate:Eu³⁺); spin-coated thin-film loading approximately 5–10 µg/cm² on quartz substrate.
• Downstream manufacturing process: Solvothermal synthesis → DMF washing → methanol solvent exchange (rate-controlled) → vacuum activation at 150°C for 12 hours → dry grinding in agate mortar → suspension in ethanol → spin-coating onto sensor substrate → N₂ drying.
• Finished product type: Luminescent thin-film sensor prototype for nitroaromatic vapor detection; not commercially available.

Solid-Phase Peptide Synthesis: 2-(4-Thiazolyl)glycine as a Conformationally Constrained Building Block

4-Thiazolecarboxylic acid is the starting material for the preparation of Fmoc-2-(4-thiazolyl)-D,L-glycine, a non-proteinogenic amino acid utilized in solid-phase peptide synthesis of protease-resistant peptide therapeutics. The synthesis route begins with Arndt-Eistert homologation of the acid to the corresponding α-amino acid via the diazoketone intermediate. On a 100-gram scale, the acid is converted to the mixed anhydride with isobutyl chloroformate in THF at −20°C, then treated with ethereal diazomethane generated in situ from N-methyl-N-nitrosourea and 40% KOH at 0°C. The diazoketone crystallizes from hexane/ethyl acetate as pale yellow needles and must be handled with exclusion of direct light; photochemical decomposition in ambient laboratory lighting occurs with a half-life of approximately 8 hours, generating nitrogen gas and a Wolff rearrangement byproduct that reduces the yield of the subsequent step. The Wolff rearrangement is conducted in tert-butanol with silver benzoate (10 mol%) as catalyst under ultrasonic irradiation at 40°C, producing the tert-butyl carbamate derivative. Acidolytic removal of the Boc group with 4N HCl/dioxane, followed by Fmoc protection with Fmoc-OSu and Na₂CO₃ in dioxane/water, yields the final protected amino acid ready for peptide synthesizer loading. The enantiomers are separated by chiral preparative HPLC on a Chiralpak IA column with hexane/isopropanol/trifluoroacetic acid (80:20:0.1) mobile phase; the D-enantiomer elutes first at 12.5 min and the L-enantiomer at 18.2 min, providing enantiomeric purity of ≥99% ee for pharmaceutical applications. Incorporation of this thiazole-containing amino acid into peptide sequences via standard Fmoc chemistry on Wang or 2-chlorotrityl chloride resin proceeds with HBTU/HOBt activation and a coupling time of 2 hours; double coupling with 3 equivalents of amino acid is advised when sterically hindered residues precede the thiazole analogue.

• Industry compliance standards: USP ⟨1043⟩ ancillary materials for cell, gene, and tissue-engineered products; Ph. Eur. 2.2.29 liquid chromatography for enantiomeric purity; ICH Q6A test procedures and acceptance criteria for new drug substances; FDA 21 CFR 211.160 laboratory controls for batch release.
• Formulation addition ratio: Amino acid loading on resin 0.3–0.5 mmol/g; coupling at 3 eq relative to resin substitution; Fmoc deprotection with 20% piperidine/DMF monitored at 301 nm UV absorbance.
• Downstream manufacturing process: Arndt-Eistert homologation → Boc protection → preparative chiral HPLC separation → Fmoc derivatization → lyophilization of purified amino acid → manual or automated SPPS coupling cycles → cleavage cocktail (TFA/TIS/H₂O, 95:2.5:2.5) → ether precipitation → preparative RP-HPLC purification → counterion exchange to acetate salt → lyophilization.
• Finished product type: Protease-stable peptide drug substance incorporating thiazole-glycine residue; candidate molecules for ghrelin receptor modulation and complement C5a antagonism.

The condensation of 4-thiazolecarboxylic acid with aniline derivatives bearing electron-donating substituents at the meta-position yields amide intermediates that serve as conformational locks in a series of non-steroidal, heterocyclic COX-2 inhibitors. The amide bond formation proceeds via activation with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 1-hydroxybenzotriazole (HOBt) in DMF at ambient temperature, but a protic solvent switch to 5% water/N-methylpyrrolidone is necessary when the aniline demonstrates poor solubility, as documented for the 3-methoxy and 3-ethoxy analogues. Residual HOBt in the isolated amide intermediate (detected by HPLC at ≥0.15 area%) causes a spurious positive result in the Ames test during genotoxicity screening, forcing an additional aqueous NaHCO₃ wash and reslurry in isopropanol to reduce HOBt to below 0.05%. The purified amide is subjected to a sulfonamide coupling with 4-sulfamoylphenylacetic acid using 1.5 equivalents of CDI in THF at 50°C, forming the bis-amide COX-2 pharmacophore. A critical in-process control at this stage is the determination of residual thiazole starting material by HPLC (limit ≤0.10%), as 4-thiazolecarboxylic acid is a known inhibitor of cytochrome P450 2C9 isoforms with an IC₅₀ of 8 µM, creating a potential drug-drug interaction liability if carried into the final active pharmaceutical ingredient. Final purification employs a Kromasil C18 column with acetonitrile/20 mM ammonium acetate gradient; the product fraction is concentrated by nanofiltration to 12% w/v and lyophilized to a white amorphous powder with ≤1.0% total impurities, conforming to ICH Q3A(R2) thresholds for a drug substance dosed at ≤200 mg/day.

• Industry compliance standards: ICH Q3A(R2) impurities in new drug substances (reporting threshold 0.05%, identification threshold 0.10%); ICH M7(R2) assessment and control of DNA-reactive impurities; Ph. Eur. 2.2.25 absorption spectrophotometry for identity confirmation; FDA guidance on drug interaction studies (CYP inhibition panels); ISO 10993-1 biocompatibility evaluation for any device combination products.
• Formulation addition ratio: Amide coupling at 1.0 eq thiazole acid to aniline; bis-amide formation at 1.5 eq CDI relative to carboxylic acid partner; target daily dose 100–200 mg in oral solid dosage form.
• Downstream manufacturing process: EDC/HOBt-mediated amidation → aqueous workup → isopropanol reslurry → vacuum drying → CDI-mediated second amidation → silica gel filtration → preparative HPLC → nanofiltration concentration → lyophilization → blending with excipients → roller compaction to granules → encapsulation.
• Finished product type: Selective COX-2 inhibitor capsule 100 mg for chronic inflammatory conditions; veterinary formulation for canine osteoarthritis.

In the synthesis of febuxostat, a xanthine oxidase inhibitor for chronic hyperuricemia, 4-thiazolecarboxylic acid is among the structural isomers evaluated during early drug discovery as the carboxylate-substituted thiazole component of the 2-arylthiazole-4-carboxylic acid scaffold. Although the clinical candidate selected the 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid regioisomer, pilot-plant procedures developed for the 4-carboxy variant remain instructive for impurity profiling during febuxostat manufacture. The 4-thiazolecarboxylic acid positional isomer is a potential process-related impurity arising when the Hantzsch thiazole synthesis precursor, thiobenzamide, undergoes cyclization with ethyl 2-chloroacetoacetate under conditions where trace moisture hydrolyzes the ester to the acid before ring closure. On a production line employing a continuous flow reactor with a PFA tube coil of 1.0 mm internal diameter at 120°C and 10 bar back-pressure, the formation of the 4-carboxy regioisomer is suppressed to 0.08 area% when the water content of the ethanol solvent is maintained below 500 ppm by Karl Fischer monitoring. The regioisomer elutes at a relative retention time of 1.24 relative to febuxostat under the compendial HPLC method of the Japanese Pharmacopoeia (JP 18) and is resolved from the main peak with a separation factor α of 1.8. Process development reports indicate that the 4-carboxy analogue demonstrates a xanthine oxidase IC₅₀ of 320 nM, approximately 40-fold less potent than febuxostat (8 nM), thus establishing the necessity of the 5-carboxy substitution pattern for optimal binding to the molybdenum cofactor domain. Removal of this positional isomer from crude febuxostat is accomplished through a pH-controlled recrystallization from 2-propanol/water at pH 4.5, where the differential pKa of the two regioisomers (3.1 vs. 3.8) enables selective precipitation.

• Industry compliance standards: JP 18 febuxostat monograph (purity by liquid chromatography); ICH Q3B(R2) impurities in new drug products; Ph. Eur. 5.27 control of impurities in substances for pharmaceutical use; EMA guideline on the specification limits for residues of metal catalysts or reagents (palladium from Heck coupling, limit 10 ppm).
• Formulation addition ratio: Key impurity controlled at ≤0.10% in febuxostat drug substance; final tablet formulation febuxostat 80 mg or 120 mg with controlled release matrix excipients.
• Downstream manufacturing process: Continuous flow Hantzsch thiazole synthesis → in-line FTIR monitoring of ester hydrolysis → pH-controlled crystallization → agitated Nutsche filtration → vacuum drying (55°C) → impurity fate and purge study as per ICH M7 → roller compaction → tableting → film coating.
• Finished product type: Febuxostat tablets 80 mg and 120 mg for gout and hyperuricemia (generic formulations); febuxostat 40 mg tablets for Japanese market.